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Abstract
Objective: To assess the microbiological effects of an antiseptic, non-alcohol based mouth-rinse containing chlo-
rhexidine and cetylpyridinium chloride, in patients undergoing radiation therapy for head-and-neck cancer.
Study Design: This was a parallel, double-blind, prospective, randomized clinical trial, including patients ir-
radiated as part of the therapy of head-and-neck cancer, aged 18-75, with at least 10 teeth, and willing to sign an 
informed consent. Cancer patients were randomly assigned to one of the two treatments (test mouth-rinse or a pla-
cebo). Three visits were scheduled (baseline, 14 and 28 days). Microbiological findings were evaluated in tongue, 
mucosa and subgingival samples, by means of culture. Microbiological variables were assessed by means of the 
Mann-Whitney, Wilcoxon and chi-square tests.
Results: 70 patients were screened and 36 were included. The detection of Candida species in mucosa and tongue 
samples showed significant reductions in the test group. Total bacterial counts decreased in both groups from 
baseline to the 2-week visit, while minor changes occurred between 2 and 4 weeks (effects on P. gingivalis, P. 
intermedia, C. rectus, E. corrodens).
Conclusions: Within the limitations of the small sample size, this study suggests that the use of the tested mouth-
rinse may lead to improvements in microbiological parameters in patients irradiated for head-and-neck cancer. 
Key words: Mucositis, head�and�nec� tumour, radiotherapy, chlorhe�idine, cetyl�pyridinium chloride, microbi�
ology.
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Introduction
Oral mucositis and xerostomia are the most common 
complications in patients undergoing non-surgical ther-
apy of cancer (1). Changes in quantity and/or quality 
of saliva may make difficult for the patient to eat or to 
use dentures, and it also leads to changes in the oral 
microbiology. The reductions in pH and in the buffer 
capacity may favour the overgrowth of opportunistic 
species (2,3). 
There is a scarcity of data on the effects of radiotherapy 
in the oral microbiota. In irradiated patients a higher 
prevalence of Candida species colonization in the oral 
cavity was reported, when compared to healthy controls 
(4). A study from Leung et al. (3) found that the sub-
gingival microflora from shallow pockets in irradiated 
patients was similar to that of gingivitis in systemically 
healthy patients, but with a tendency to show the over-
growth of non-typical oral species, including fungi. 
When irradiated patients were evaluated 6 months after 
cancer therapy (5), a transient colonization with aerobic 
and anaerobic facultative rods and gram-negative cocci 
was observed. Six to eight months after therapy, Can�
dida sp. and especially enterics were more frequently 
detected in previously irradiated patients, as compared 
with controls (6). Other studies have focussed on the 
changes in caries-associated microflora. One group 
reported a high incidence of caries “radiation caries”, 
due to the long-term radiotherapy-induced changes in 
the microflora (7). In another study, an overgrowth of 
Streptococcus mutans was not observed, but other non-
mutans streptococci were isolated (8), in contrast to an-
other study in children aged 4-15 years, which reported 
significantly higher S. mutans counts as compared with 
controls (9).
Numerous studies in systemically healthy patients have 
demonstrated that chlorhexidine (CHX) can reduce bac-
terial and mycotic colonization of the oral cavity (10). 
Different CHX formulations have been recently intro-
duced in the market with the aim of reducing its side 
effects (for example, by eliminating alcohol from the 
formulations) or to increase its antimicrobial activity 
(for example, by adding new active agents). However, 
these new formulations must demonstrate the bio-avail-
ability of CHX and therefore, its antimicrobial activity. 
One of these new formulations lacking alcohol content 
and combined with an additional active agent (cetyl-py-
ridinium chloride, CPC), has been marketed (PerioAid 
Tratamiento® and PerioAid Mantenimiento®, Dentaid, 
Cerdanyola del Vallés, Spain) and proved to be both safe 
and effective, at standard 0.12% concentration (11,12) or 
even at a lower concentration (0.05%) (13,14). 
In summary, radiotherapy for HNT induces important 
oral side effects, such as xerostomia and mucositis, and 
these changes may favour mucosal and saliva coloniza-
tion by opportunistic microorganisms (Candida sp.), as 
well as the overgrowth of anaerobic bacterial species, 
with the subgingival flora as primary niche. Our hy-
pothesis is that the use of an effective antiseptic mouth 
rinse (combining CHX and CPC) would prevent this 
overgrowth and may help to maintain a more health-
related flora in the mouth. It is, therefore, the objective 
of investigation was to assess the microbiological ef-
fects of an antiseptic, non-alcohol based, mouth rinse 
containing CHX and CPC, in head-and-neck cancer 
patients under irradiation therapy. Clinical results have 
described in a previous paper (15)
Patients and Method
Patients
A total of 70 Consecutive patients were selected at the 
Oncology Radiotherapy Service at the “12 de Octubre” 
Hospital (Madrid), using the criteria already described 
in Lanzos et al. (15), including patients irradiated as 
part of the therapy of head-and-neck cancer, aged 18-75, 
with at least 10 teeth, and willing to sign an informed 
consent. Patients were excluded if they were already 
diagnosed of suffering a mucosal pathology, such as li-
chen or lupus. 
Finally, 36 patients (32 male and 4 female patients) were 
included. All suffered from head-and-neck cancer and 
their oncology therapy included radiation in doses rang-
ing from 50-80 Gy, delivered in 5 periods. In the test 
group, the patients mean age was 49.4 (standard devi-
ation-sd-15.4) ranging 24-72. In the control group the 
mean age was 54.3 (sd 16.1) with a range between 24-75. 
Only one female was enrolled in the control group, and 
three in the test group. Three test patients and six con-
trol patients were smokers at the baseline.
Methods
Study design
The study was a parallel, double-blind, prospective, 
randomised clinical trial.
Patients were screened for compliance with the inclu-
sion and exclusion criteria and once they agreed to 
participate by signing the IRB (Institutional Review 
Board) approved informed consent; they were entered 
in the study and appointed for the baseline visit.
The study consisted on three visits:
•  Visit 1 or baseline: the day when radio-therapy was 
started.
•  Visit 2: 14 days after baseline.
•  Visit 3 or final visit: 28 days after baseline.
-  Visit 1. Baseline. Patients were examined, outcome 
variables were recorded and samples for microbiology 
were collected.  After this evaluation, all participating 
patients were randomised and the treatments were al-
located by providing the assigned mouth rinse together 
with the instructions for use. They were then appointed 
for the next visit according to the study plan.
-  Visit 2. 14-day evaluation. The same sampling and 
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registration of outcome variables were done again, to-
gether with an interview with the patient assessing their 
compliance in using the assigned mouth rinse and the 
occurrence of any adverse event. 
-  Visit 3. Final visit after 28 days. Identical to visit 2, the 
sampling, registration of outcome variables, compliance 
and occurrence of any adverse event were carried out.
All the outcome variables were assessment by a single 
and calibrated examiner, who was blinded to the treat-
ment assignment. 
Outcome variables
Evaluation of Mucositis
The Scale of the Radiation Therapy Oncology Group/
European Organization Research and Treatment of 
Cancer (RTOG/EORTC) (16) was utilized. The clinical 
results have been described in other paper (15).
Tongue samples
Samples from the tongue dorsum were obtained by 
means of a tongue scrapper (Halita®, Dentaid, Cerdan-
yola del Vallés, Spain), and a standardised loop of 0.5 
mm. The methods were identical to those described in 
(13). Briefly, the scrapper was used to take tongue coat-
ing from the dorsum of the tongue, and the loop was 
used to collect a standardised amount of the coating 
from the scrapper. This amount was transferred to a 1 
mL Reduced Transport Fluid or RTF(17) vial and trans-
ported to the laboratory. At the laboratory, the sample 
was dispersed, serially diluted and inoculated on agar 
Saboreaud, to detect Candida species.
Mucosa samples
Samples from the buccal mucosa were obtained by gen-
tle striking of the buccal mucosa in both sides with a 
cotton swab, for a few seconds. After that, the cotton 
swab was kept in its transport tube with 2 mL of RTF, 
and was transported to the laboratory, where the sam-
ples were processed as described for tongue samples. 
Subgingival samples
Subgingival samples were collected from four selec-
ted sites. Sites with the worse clinical condition were 
selected, based on probing pocket depth and bleeding, 
considering also ease of access to avoid contamination, 
and usually mesio-buccal sites were selected. At sites, 
supragingival plaque was carefully removed to avoid 
bleeding using sterile gauze and / or curettes. Then, 
these sites were dried with sterile cotton rolls and gentle 
air drying. Two consecutive sterile paper points (me-
dium size, Maillefer, Ballaigues, Switzerland) were 
inserted as deep as possible in the pocket, and left in 
place for 10 seconds. The paper points were transferred 
to a vial containing 1.5 mL of RTF, and pooled with all 
the other paper points. The vial was sent to the labora-
tory and processed within 24 hours. At the laboratory, 
vials were vortexed (30 seconds), serially diluted, and 
plated in two different media:  Blood agar medium (No. 
2 of Oxoid; Oxoid Ltd., Basingstoke, England), with 
5% horse blood, and haemin (5 mg/l) and menadione (1 
mg/l) and Dentaid-1 medium (18). The blood agar plates 
were studied after 7 and 14 days of anaerobic incubation 
(80% N2; 10% H2; 10% CO2 at 37ºC); and the Dentaid-1 
plates after 3-5 days of 37ºC incubation in air with 5% 
CO2.  Plates were carefully examined for the identifica-
tion of Aggregatibacter actinomycetemcomitans, Por-
phyromonas gingivalis, Prevotella intermedia/nigres-
cens, Tannerella forsythia, Parvimonas micra, Capno-
cytophaga sp., Eikenella corrodens and Fusobacterium 
sp., based on the morphology of the colony and using di-
fferent standard biochemical tests to confirm the initial 
identification (RAPID ANA II). Other relevant colonies 
(those representing an important proportion of the flora) 
will be also isolated for further characterization. Colo-
nies of each bacterial species will be counted, as will 
be the total number of colonies in a representative plate 
(between 30 to 300 colonies). Counts of A. actinomy�
cetemcomitans will be performed on Dentaid-1 plates, 
based on its typical colony morphology, a catalase reac-
tion and a set of specific enzymes. Additionally, any co-
lony growing on Dentaid-1 medium, suspected of being 
an enteric rod, will be isolated. Dentaid-1 medium, as 
TSBV medium (19), have demonstrated excellent reco-
very of Enterobacteriaceae and Pseudomonadaceae 
species. Suspect non-oral, gram-negative, facultative 
anaerobic rods (20) will be subcultured on McConkey 
agar, purified and classified using a commercial identi-
fication kit system (API 20 E, Baxter Healthcare, West 
Sacramento, CA, USA). The panels and bacterial inocu-
lae will be prepared following the recommendations of 
the manufacturer, and incubated for 18-24 hours at 35ºC 
in non-CO2 incubator. Bacterial speciation, based on 34 
taxonomic test reactions, was performed using the soft-
ware provided by the manufacturer.
Treatments
Patients included in the study were randomly assigned 
to one of the two treatments, either test or control. Ran-
domisation was done through a computer-generated list 
that assigned treatments by numbers. Patients received a 
number after inclusion, corresponding to a numerically 
coded mouth rinse. The list and the numbered bottles were 
provided by the promoter, and the assignation of numbers 
was made by the researchers in consecutive order. Codes 
were not opened until the end of the study. Both patients 
and researchers were blinded throughout the study.
Patients in the test group rinsed with Perio-Aid Trata-
miento® (Dentaid, Cerdanyola del Valles, Spain) com-
posed of 0.12% CHX and 0.05% CPC as active ingre-
dients. Patients in the control group rinsed with a place-
bo mouth rinse, identical to the test product but without 
the active components. Both formulations lacked any 
alcohol. 
All patients received written instructions on the use of 
their assigned treatment. In brief, they should carry out 
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their usual tooth-brushing and oral hygiene procedures, 
and then they should rinse with 15 mL of the assigned 
product, for 30 second, twice a day (morning and eve-
ning). Compliance was assessed by asking the patients 
to return the used bottles and by a brief interview.
Statistical analyses
The primary outcome variables were the presence/ab-
sence of pathogens (the most reliable microbiological 
variable in anaerobic culture) and the counts of Candida 
sp. in agar Saboreaud. 
Microbiological variables were assessed either as inter-
group changes, compared by means of the Mann-Whit-
ney test, or intra-group changes, studied with the Wil-
coxon test. The frequency of detection was compared 
by means of chi-square test.
Changes in the degree of mucositis were evaluated by 
means of the chi-square test with the Yates s´ correction. 
Comparisons between groups were assessed by means 
of the Mann-Whitney test. 
The level of significance was established in p<0.05, and 
tendencies towards significance were considered for p<0.1. 
No corrections for multiple comparisons were made.
The sample size was estimated, based on previous stud-
ies using microbiological outcome variables (21,22), to 
be of, at least, 15 patients per arm.
Results
Demographic data 
Demographic data of the population has been described 
in the Material and Methods section. No statistically 
significant differences were detected in demographic 
data between groups. 
Detection of Candida spp. in mucosa (Table 1)
In mucosa samples, minor changes were detected in 
the control group throughout the whole study period. 
Conversely, reductions were observed in the test group, 
from baseline to 4 weeks (p=0.05) and from 2 weeks to 
4 weeks (p=0.09) that showed a tendency towards sta-
tistical significance.
Detection of Candida spp. in tongue samples (Table 2)
In tongue samples, a similar trend was found: minor 
changes or increases in the control group, while impor-
tant reductions in the test group. However, none of the 
differences were statistically significant.
Microbiological findings in subgingival samples
Total bacterial counts decreased in both groups from 
baseline to the 2-week visits, while minor changes oc-
curred between 2 and 4 weeks. No statistically signifi-
cant differences were detected both in intra- or inter-
group comparisons (Table 3).
The most frequently isolated bacterial species at base-
line were F. nucleatum (68.8-85.7%), P. intermedia 
(50.0-71.4%) and P. gingivalis (42.9-43.8%). They also 
represented the highest proportions of flora (Table 4).
P. gingivalis demonstrated a clear decrease in preva-
lence from baseline to 4 weeks (p=0.007) in the test 
group, while the placebo group did not show variations. 
Intergroup differences after 4 weeks were statistically 
significant (p=0.023). 
P. intermedia showed an increase in frequency of detec-
tion in the placebo group, and minor changes in the test 
group, leading to significant differences in the inter-
group comparison at the 4-week visit (p=0.023).
A similar trend was observed for C. rectus, with sig-
nificant reductions baseline-4 weeks in the test group 
(p=0.031). The reduction in the frequency of detection 
CONTROL baseline week2 week4 base-w2 base-w4 w2-w4 
n 14 10 9 10 9 9 
mean 231 30 26 2 -5 -6 
SD 542 54 30 25 71 56 
       
TEST baseline week2 week4 base-w2 base-w4 w2-w4 
n 16 12 11 12 11 11 
mean 715 684 38 -7 -716 -708 
SD 1188 1178 62 1727 1195 1185 
       
p value* 0.327 0.765 0.760 0.448 0.175 0.131 
CONTROL p value **  > 0.999 0.734 0.734 
TEST p value ** 0.844 0.055 0.098 
Table 1. Candida sp. in mucosa samples (in colony forming units).
* Mann-Whitney test for intergroup comparison.
** Wilcoxon matched-pairs signed-ranks for intragroup comparison.
Base-baseline, 2w-2 weeks, 4w-4 weeks, SD-standard deviation.
Base-w2, base-w4 and w2-w4, represents changes between visits, with positive values 
meaning increase and negative values decrease.
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of E. corrodens was also statistically significant in the 
test group both after 2 weeks (p=0.021) and after 4 
weeks (p=0.034).
Minor changes with non significant differences were 
detected for other bacterial species.
No clear trends were observed for mean counts and 
mean proportions of flora of bacterial species (Table 4).
No overgrowth of other opportunistic species was de-
tected.
Adverse effects
No relevant adverse effects were reported in any group.
Discussion
The results from the present study have shown some rel-
evant microbiological effects when using a non-alcohol, 
CHX and CPC based mouth rinse, in patients undergo-
ing radiation therapy as part of the treatment of a head-
and-neck cancer. These results, however, should be in-
terpreted with caution, due to the limited sample size 
and the limitations of its calculation, the heterogeneity 
of the patient sample (including smoking habit) and the 
inherent difficulties when enrolling patients with severe 
health conditions in clinical trials. In addition, no clini-
cal effects (15) were associated to the improvements in 
the microbiological variables.
There are many confounding factors that may have in-
fluenced the results, such as: the total radiation dose 
and treatment regimen; the heterogeneity of the patient 
sample due to differences in tumour type, clinical stage, 
histology, location, extension, etc, and the existence of 
previous or concomitant chemotherapy. Moreover, the 
deterioration of the patient systemic status during the 
CONTROL baseline week2 week4 base-w2 base-w4 w2-w4 
n 12 10 9 9 8 9 
mean 17 45 136 33 135 86 
SD 29 115 377 118 393 258 
       
TEST baseline week2 week4 base-w2 base-w4 w2-w4 
n 15 12 9 11 8 9 
mean 682 376 85 -527 -1102 -324 
SD 1826 882 159 2379 2494 1032 
       
p value* > 0.999 0.974 0.505 0.568 0.279 0.354 
CONTROL p value **  0.195 0.547 0.945 
TEST p value ** 0.945 0.312 0.312 
Table 2. Candida sp. in tongue samples (in colony forming units).
* Mann-Whitney test for intergroup comparison.
** Wilcoxon matched-pairs signed-ranks for intragroup comparison.
Base-baseline, 2w-2 weeks, 4w-4 weeks, sd-standard deviation.
Base-w2, base-w4 and w2-w4, represents changes between visits, with positive values 
meaning increase and negative values decrease.
baseline week 2 week 4 
baseline-
week 2 
baseline-
week 4 
week 2-
week 4 
placebo 
n 12 10 9 8 7 9 
mean 6.829 6.192 6.278 -0.659 -0.427 0.193 
SD 0.544 0.874 0.71 0.762 0.526 0.616 
test 
n 13 11 9 8 7 9 
mean 6.331 5.745 5.906 -0.093 -0.017 -0.006 
SD 1.079 0.928 0.89 0.904 0.596 0.537 
inter group t-test 0.165 0.271 0.342 0.197 0.198 0.477 
Table 3. Subgingival samples: total log of colony forming units expressed as mean and standard deviation 
(SD) per visit and in changes between visits.
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oncology therapy, precluded some patients from con-
tinuing the study and therefore, to comply with the pro-
grammed study visits. 
Previous studies have reported changes in the oral mi-
croflora as a consequence of irradiation therapy, includ-
ing an increase in the detection of Candida sp. (2,4,23), 
an increase in oral colonization of aerobic and anaerobic 
gram-negative rods and cocci (5), an increase in the de-
tection of caries-associated micro-organisms (7,8,9), and 
changes in the subgingival microflora with an increase 
in the presence of non-oral micro-organisms (3,6). In the 
present study, the use of the evaluated mouth rinse with 
CHX and CPC, was associated with significant micro-
biological benefits, both at subgingival (effects on P. gin�
givalis, P. intermedia, C. rectus, E. corrodens), tongue 
(Candida sp.), and mucosal (Candida sp.) samples. A 
similar impact, although not statistically significant was 
reported by Ferretti et al. (21) in the group of 30 irradia-
ted patients, with a reduction in oral streptocci and yeasts 
in the group using 0.12% CHX, t.i.d. Conversely, in other 
study also with 30 patients, the group using 0.1% CHX, 
q.i.d., had similar colonization patterns that the control 
group in terms of Candida sp., staphylococci, and other 
super infecting microorganisms (22). One of the explana-
tions for the positive results in our study could be related 
to the improved formulation of the tested product, thus 
providing higher activity (11,12). 
In the present study, three oral niches were samples, the 
Table 4. Subgingival samples: colony forming units (cfu), proportions of flora and frequency of detection of different periodontal pathogens 
at every study visit.
  A. actinomycetemcomitans P.gingivalis P.intermedia 
group variable baseline week 2 week 4 baseline week 2 week 4 baseline week 2 week 4 
PLACEBO 
n samples 14 10 9 14 10 9 14 10 9 
mean cfu 4714 0 0 161700 210540 742867 398451 126720 316360 
mean proportion (%) 0.04 0.00 0.00 6.85 5.70 10.46 4.05 4.84 4.39 
positive samples 1 0 0 6 4 4 10 6 9 
frequency of detection 7.1% 0.0% 0.0% 42.9% 40.0% 44.4% 71.4% 60.0% 100.0% 
TEST 
n samples 16 12 11 16 12 11 16 12 11 
mean cfu 0 7260 684 178679 144870 0 185076 137830 223320 
mean proportion (%) 0.00 0.05 0.02 0.65 1.41 0.00 0.71 3.64 3.61 
positive samples 0 1 1 7 4 0 8 9 5 
frequency of detection 0.0% 8.3% 9.1% 43.8% 33.3% 0.0% 50.0% 75.0% 45.5% 
  P.micra F.nucleatum C.rectus 
group variable baseline week 2 week 4 baseline week 2 week 4 baseline week 2 week 4 
PLACEBO 
n samples 14 10 9 14 10 9 14 10 9 
mean cfu 4714 21120 35200 480716 184708 156127 0 660 4400 
mean proportion (%) 0.31 0.98 0.93 6.00 6.51 4.91 0.00 0.03 0.31 
positive samples 2 3 3 12 10 9 0 1 3 
frequency of detection 14.3% 30.0% 33.3% 85.7% 100.0% 100.0% 0.0% 10.0% 33.3% 
TEST 
n samples 16 12 11 16 12 11 16 12 11 
mean cfu 13613 2145 13140 273137 48351 86220 1246 550 1200 
mean proportion (%) 0.23 1.77 2.57 2.09 4.75 3.14 0.07 0.03 0.03 
positive samples 3 3 4 11 10 7 3 1 1 
frequency of detection 18.8% 25.0% 36.4% 68.8% 83.3% 63.6% 18.8% 8.3% 9.1% 
  E.corrodens T.forsythia Capnocytophaga sp. 
group variable baseline week 2 week 4 baseline week 2 week 4 baseline week 2 week 4 
PLACEBO 
n samples 14 10 9 14 10 9 14 10 9 
mean cfu 23760 726 29333 10513 0 10267 1933 2640 0 
mean proportion (%) 0.59 0.10 0.25 0.30 0.00 1.02 0.07 0.12 0.00 
positive samples 2 2 1 2 0 2 3 2 0 
frequency of detection 14.3% 20.0% 11.1% 14.3% 0.0% 22.2% 21.4% 20.0% 0.0% 
TEST 
n samples 16 12 11 16 12 11 16 12 11 
mean cfu 2500 0 0 0 0 0 28875 0 0 
mean proportion (%) 0.22 0.00 0.00 0.00 0.00 0.00 0.52 0.00 0.00 
positive samples 5 0 0 0 0 0 2 0 0 
frequency of detection 31.3% 0.0% 0.0% 0.0% 0.0% 0.0% 12.5% 0.0% 0.0% 
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subgingival niche for the evaluation of anaerobic bacte-
ria and the tongue and saliva for the evaluation of Candi�
da sp. The evaluation of the subgingival microflora was 
selected in order to provide a representative overview of 
the presence of anaerobic bacteria in the mouth, since 
most anaerobic bacteria have their primary site in this 
area and their subgingival presence is associated with 
its presence in other intraoral sites (13, 24). Anaerobic 
bacteria could be related with worsen of the mucositis 
lesions by contamination, especially in the ulcerative 
phase (25). Conversely, the subgingival area is not the 
primary site for Candida sp. and other intraoral sites 
were evaluated to assess its presence.
The impact of the use of the evaluated mouth rinse in the 
detection of Candida sp. may suggest that CHX mouth rinse 
could be a reasonable alternative in the prevention of candi-
diasis in risk patients. Some authors have also suggested its 
use in the treatment for oral fungal infections, as alternative 
for nystatin rinses, clotrimazole or ketoconazole (26).
It is clear that the potential benefit of this preventive 
regime using an antimicrobial rinse relies more in the 
control of oral micro-organisms and in the reduction in 
oropharyngeal candidosis, rather than on a direct effect 
upon oral mucositis.
Conclusions
Within the limitations of the small sample size, this 
study suggests that the use of a 0.12% CHX and 0.05% 
CPC mouth rinse may lead to improvements in micro-
biological parameters in patients irradiated for head-
and-neck cancer. 
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